AzTrials
AzTrials

Neurological DisordersAFTERNCT07299344

A Model for Continuous Care of Fragile Patients

An observational study of Neurological Disorders and Orthopedic Disorders, run by Azienda Sanitaria Locale CN2 Alba-Bra at 1 site in Italy.

Not yet recruiting

Opening soon. The study is approved but enrolment has not started yet. Sites may already take enquiries.

Sites and contacts
Official record
Search all trials

Trial summary

This observational study aims to monitor functional status and identify potential declines in the functioning of medically fragile patients with neurological and/or orthopedic conditions, representing an added value for ensuring appropriate patient management. Read more about this study

Who is it for?
Ages 18 years and older
What is being tested?
Telemedicine-Based Functional Monitoring
How many people
100 participants
Where
1 siteItaly
Study dates
Dec 2025to Jun 2028
Phase
Observational
Are there results?
Not yet: the study is under way

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 years and older
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Study population: Medically fragile patients with various neurological or orthopedic conditions will be recruited from Casa di Cura "La Residenza" in Rodello (CN - Italy) for intensive rehabilitation. Patients will come from the Neurology and Orthopedics Units of Michele e Pietro Ferrero Hospital in Verduno (CN - Italy) - ASL CN2 .

Who may be able to join

  • Adult medically fragile patients with one of the following neurological conditions: mild-to-moderate stroke (Rankin ≤ 3), Multiple Sclerosis (EDSS ≤ 6.5), Parkinson's disease or parkinsonisms, neuromuscular diseases; or orthopedic conditions: femur, pelvis, or humerus fracture.
  • Able to walk independently, with or without assistive devices.
  • Adequate cognitive function (MMSE ≥ 24).
  • Patient or caregiver owns and can use a mobile device with internet/data connection.
  • Presence of a cognitively capable, cooperative caregiver willing to participate in the study.

Who cannot join

  • Patients with severe neurological or orthopedic conditions who cannot walk independently, even with assistive devices.
  • Patients with moderate or severe cognitive impairment (MMSE < 24).
  • Patients with Barthel Index > 60.
  • Patients or caregivers unable to use a mobile device or without internet/data connection.
  • Patients without a cooperative, cognitively capable caregiver.

Trial locations and contacts

1 site in 1 country. Contact the study team or a site near you to ask about taking part.

Michele Dotta, Dr. contact

+39.0172.1408670

mdotta@aslcn2.it

Italy1 site
  • Azienda Sanitaria Locale CN2 Alba-Bra, Ospedale Michele e Pietro Ferrero

    Verduno, CN, 12060

Other trials in Italy

About this study

Official title: Un Modello di Presa in Carico Continua Del Paziente Fragile

This observational study aims to monitor functional status and identify potential declines in the functioning of medically fragile patients with neurological and/or orthopedic conditions, representing an added value for ensuring appropriate patient management. This approach improves system efficiency and supports a proactive strategy that promotes the appropriate use of resources.

Read the detailed description

This is a prospective, observational, non-profit study.

Primary Objective:

To compare functional and cognitive test results at discharge from "La Residenza" rehabilitation center (Rodello - CN- Italy) with remote assessments at patients' homes, demonstrating that Timed Up and Go (TUG) and GPCog tests, validated in-person, can be reliably administered via telemedicine.

Secondary Objectives:

To monitor motor and cognitive function remotely at 3, 6, and 12 months after discharge, assessing clinical course and disease progression, and evaluating patient condition as stable, improved, or deteriorated.

Study Timeline and Sample Size:

Recruitment is expected from September 2025 to March 2026, with last follow-up in March 2027 and an additional 6 months for data analysis and publication. A total of 100 patients (50 orthopedic, 50 neurological) will be enrolled, accounting for a 25% expected loss, based on power calculations for paired t-tests comparing in-person and remote assessments.

Being tested
Telemedicine-Based Functional Monitoring
Keywords
Functional Monitoring, Functional Decline, Medically Fragile Patients, Neurological Disorders, Orthopedic Conditions, Rehabilitation, Proactive Care Model, Continuous Patient Management, Rehabilitation Setting, Early Detection of Functional Changes, telemedicine
Medical subject headings
Nervous System Diseases, Musculoskeletal Diseases

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Telemedicine-Based Functional MonitoringOther

    Also called Remote Functional Assessment Protocol, Telemedicine Follow-Up Monitoring

    This intervention provides structured functional monitoring of medically fragile patients with neurological and/or orthopedic conditions using telemedicine. Patients undergo MMSE, Rankin Scale, Barthel Index, TUG, GPCog, and SF-36 assessments at discharge and during follow-up at 3, 6, and 12 months. Patient and caregiver satisfaction with remote monitoring is also evaluated. All remote assessments are performed via the TESI eViSus BioCare® system on mobile devices, allowing early detection of functional decline and supporting proactive patient management.

Study groups in NCT07299344
Study groupRoleWhat they receive
Medically Fragile Patients with Neurological or Orthopedic ConditionsThis cohort includes medically fragile adult patients with mild-to-moderate neurological or orthopedic conditions who are able to ambulate independently with or without assistive devices. Eligible neurological conditions include mild-to-moderate stroke (mRS ≤ 3), Multiple Sclerosis (EDSS ≤ 6.5), Parkinson's disease or parkinsonisms, and neuromuscular diseases. Eligible orthopedic conditions include femur, pelvis, or humerus fractures. Participants must have adequate cognitive function (MMSE ≥ 24) and the presence of a cognitively capable caregiver.
Receives: Other: Telemedicine-Based Functional Monitoring

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Concordance Between In-Person and Telemedicine Assessments of Functional and Cognitive Performance

    Percentage of patients for whom the Timed Up and Go (TUG) test differs by less than 3.5 seconds and the GPCog test differs by less than 3 points between in-person and telemedicine assessments.

    Measured: 5-10 days after discharge

Secondary outcomes (7)
  1. Timed Up and Go (TUG) Test Performance

    The Timed Up and Go (TUG) test assesses functional mobility by measuring the time it takes (in seconds) for a participant to stand up from a chair, walk 3 meters, turn, walk back, and sit down. Lower times indicate better functional mobility.

    Unit of Measure: Seconds (s)

    Measured: 3, 6, and 12 months after discharge

  2. General Practitioner Assessment of Cognition (GPCog) Score

    General Practitioner Assessment of Cognition (GPCog), total score range 0-9. Higher scores indicate better cognitive functioning.

    Unit of Measure: Score on a scale (0-9)

    Measured: 3, 6, and 12 months after discharge

  3. Modified Rankin Scale (mRS)

    Modified Rankin Scale score assessing global disability. Range 0-6, where 0 = no symptoms and 6 = death. Higher scores indicate worse disability.

    Unit of Measure: Score on a scale (0-6)

    Measured: Baseline and 12 months after discharge

  4. Barthel Index for Activities of Daily Living

    Barthel Index score assessing independence in activities of daily living. Range 0-100. Higher scores indicate greater independence.

    Unit of Measure: Score on a scale (0-100)

    Measured: Baseline and 12 months after discharge

  5. SF-36 Composite Scores (Physical and Mental Component Summaries)

    Short Form-36 (SF-36) Health Survey assessing quality of life across multiple domains. Scores range 0-100 for each domain. Higher scores indicate better perceived health status.

    Unit of Measure: Score on a scale (0-100)

    Measured: At discharge and 12 months after discharge

  6. Patient Satisfaction With Remote Monitoring

    Patient satisfaction assessed using a validated satisfaction questionnaire (e.g., Likert scale 1-5). Higher scores indicate greater satisfaction.

    Unit of Measure: Score on a Likert scale (1-5)

    Measured: 3, 6, and 12 months after discharge

  7. Caregiver Satisfaction With Remote Monitoring

    Caregiver satisfaction assessed using a validated satisfaction questionnaire (e.g., Likert scale 1-5). Higher scores indicate greater satisfaction.

    Unit of Measure: Score on a Likert scale (1-5)

    Measured: 3, 6, and 12 months after discharge

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted23 Dec 2025
  2. Study startDec 2025 (estimated)
  3. Primary completionJun 2028 (estimated)
  4. Study completionJun 2028 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Observational
Observational model
Cohort
Time perspective
Prospective
Enrolment
100 participants (estimated)
IDs, dates and publications
ClinicalTrials.gov ID
NCT07299344
Sponsor's protocol ID
AFTER
Acronym
AFTER
Status last verified
Dec 2025
First submitted
28 Nov 2025
Last updated
23 Dec 2025
Results posted
No
Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
Undecided

Publications

  • Feeney J, Savva GM, O'Regan C, King-Kallimanis B, Cronin H, Kenny RA. Measurement Error, Reliability, and Minimum Detectable Change in the Mini-Mental State Examination, Montreal Cognitive Assessment, and Color Trails Test among Community Living Middle-Aged and Older Adults. J Alzheimers Dis. 2016 May 31;53(3):1107-14. doi: 10.3233/JAD-160248.

    PubMed 27258421
  • Giavarina D. Understanding Bland Altman analysis. Biochem Med (Zagreb). 2015 Jun 5;25(2):141-51. doi: 10.11613/BM.2015.015. eCollection 2015.

    PubMed 26110027
  • Viglino G, Neri L, Barbieri S, Tortone C. Peritoneal dialysis training performed remotely: results and comparison with Home Training. Clin Exp Nephrol. 2023 Jan;27(1):72-78. doi: 10.1007/s10157-022-02276-z. Epub 2022 Sep 21.

    PubMed 36129554
  • Brodaty H, Pond D, Kemp NM, Luscombe G, Harding L, Berman K, Huppert FA. The GPCOG: a new screening test for dementia designed for general practice. J Am Geriatr Soc. 2002 Mar;50(3):530-4. doi: 10.1046/j.1532-5415.2002.50122.x.

    PubMed 11943052
  • van Dyck CH, Swanson CJ, Aisen P, Bateman RJ, Chen C, Gee M, Kanekiyo M, Li D, Reyderman L, Cohen S, Froelich L, Katayama S, Sabbagh M, Vellas B, Watson D, Dhadda S, Irizarry M, Kramer LD, Iwatsubo T. Lecanemab in Early Alzheimer's Disease. N Engl J Med. 2023 Jan 5;388(1):9-21. doi: 10.1056/NEJMoa2212948. Epub 2022 Nov 29.

    PubMed 36449413
  • de Joode SGCJ, Kalmet PHS, Fiddelers AAA, Poeze M, Blokhuis TJ. Long-term functional outcome after a low-energy hip fracture in elderly patients. J Orthop Traumatol. 2019 Apr 11;20(1):20. doi: 10.1186/s10195-019-0529-z.

    PubMed 30976999

Questions about this trial

What is this clinical trial studying?

An observational study of Neurological Disorders and Orthopedic Disorders, run by Azienda Sanitaria Locale CN2 Alba-Bra at 1 site in Italy.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 5 inclusion and 5 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: opening soon, as of the sponsor's last update on 23 Dec 2025. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in Italy. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

This study is still under way. Results are not available in the source record yet.

How can a doctor refer a patient or contact the research team?

Contact Michele Dotta, Dr. (+39.0172.1408670, mdotta@aslcn2.it), or a site near the patient. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Concordance Between In-Person and Telemedicine Assessments of Functional and Cognitive Performance (time frame: 5-10 days after discharge). It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT07299344, which also lists 6 linked publications.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 23 Dec 2025.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in